Latest Share Chat

REMOVE ADS

Immupharma Regulatory News (IMM)

Immupharma Information

Share Price Information for Immupharma (IMM)

Share Price is delayed by 15 minutes

Get Live Data

4.405 0.00 (0.00%)

Bid:

4.405

Ask:

4.58

Spread: 0.175 (3.973%)

Market Cap: £27.48m

Last checked at -

Intraday Immupharma Share Chart

REMOVE ADS

Share Price Volatility

11 Dec 2019 12:49

RNS Number : 5515W

Immupharma PLC

11 December 2019

ImmuPharma PLC

("ImmuPharma" or the "Company")

SHARE PRICE VOLATILITY

ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces that following the recently announced licensing and development agreement with Avion, the US speciality pharmaceutical company, in which Avion will fund an international Phase III trial for our lead programme, Lupuzor™, we note the volatility in the Company's share price and speculation concerning a possible fundraising. The Board can confirm that the Company is adequately funded and has no intention of raising funds.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")

For further information please contact:

ImmuPharma PLC (www.immupharma.com) Tim McCarthy, Chairman	+ 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Vassil Kirtchev Stanford Capital Partners (Joint Broker) Patrick Claridge, John Howes SI Capital (Joint Broker) Nick Emerson	+44 (0) 203 368 8974 +44 (0) 203 815 8880 +44 (0) 1483 413500

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. For additional information about ImmuPharma please visit www.immupharma.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCBDBDDLSBBGCB

Date		Source	Headline
29th Sep 2022	4:40 pm	RNS	Second Price Monitoring Extn
29th Sep 2022	4:37 pm	RNS	Price Monitoring Extension
14th Sep 2022	10:04 am	RNS	Written Response received from the FDA
7th Sep 2022	8:25 am	RNS	Exercise of Options
31st Aug 2022	7:00 am	RNS	FDA response for Type C Meeting - update
30th Aug 2022	11:29 am	RNS	Exercise of Options
24th Aug 2022	8:11 am	RNS	Exercise of Options
17th Aug 2022	6:12 pm	RNS	TR-1 Notification of major holdings
16th Aug 2022	8:03 am	RNS	Total Voting Rights
11th Aug 2022	7:00 am	RNS	Result of Broker Option / PDMR Dealings
4th Aug 2022	7:00 am	RNS	Investor Presentation - Investor Meet Company
3rd Aug 2022	4:40 pm	RNS	Second Price Monitoring Extn
3rd Aug 2022	4:35 pm	RNS	Price Monitoring Extension
3rd Aug 2022	4:33 pm	RNS	Subscription/Placing to raise £1.1m; Broker Option
26th Jul 2022	4:41 pm	RNS	Second Price Monitoring Extn
26th Jul 2022	4:35 pm	RNS	Price Monitoring Extension
11th Jul 2022	7:00 am	RNS	Initiation of Research
7th Jul 2022	7:00 am	RNS	Confirmed FDA response date for Type C Meeting
28th Jun 2022	5:44 pm	RNS	Admission of new ordinary shares of £0.01
28th Jun 2022	11:42 am	RNS	Result of AGM
27th Jun 2022	7:00 am	RNS	Update on Lupuzor
20th Jun 2022	3:22 pm	RNS	Holding(s) in Company
1st Jun 2022	7:00 am	RNS	Notice of AGM & Annual Report & Accounts
25th May 2022	7:00 am	RNS	Finals results for y/e 31 December 2021
4th May 2022	7:00 am	RNS	UPDATE on LUPUZOR™ PROGRESS to PHASE 3 with AVION
13th Apr 2022	7:00 am	RNS	UPDATE on P140 (LUPUZOR™) clinical progress
7th Feb 2022	7:00 am	RNS	LUPUZOR UPDATE
10th Jan 2022	7:00 am	RNS	TR-1: Notification of major holdings
5th Jan 2022	9:53 am	RNS	TR-1: Notification of major holdings
24th Dec 2021	8:34 am	RNS	Holding(s) in Company
20th Dec 2021	7:00 am	RNS	Subscriptions and Placing to raise £3.55 million
15th Dec 2021	4:35 pm	RNS	Price Monitoring Extension
7th Dec 2021	4:41 pm	RNS	Second Price Monitoring Extn
7th Dec 2021	4:36 pm	RNS	Price Monitoring Extension
29th Nov 2021	7:00 am	RNS	COLLABORATION WITH IMPERIAL COLLEGE LONDON
18th Nov 2021	7:00 am	RNS	Corporate Update
8th Nov 2021	4:41 pm	RNS	Second Price Monitoring Extn
8th Nov 2021	4:36 pm	RNS	Price Monitoring Extension
11th Oct 2021	4:35 pm	RNS	Price Monitoring Extension
1st Oct 2021	7:00 am	RNS	Euronext Delisting
30th Sep 2021	7:15 am	RNS	PROF. SYLVIANE MULLER AWARDED ‘LEGION D’HONNEUR’
29th Sep 2021	7:30 am	RNS	Interim Results for the 6months ended 30 June 2021
29th Sep 2021	7:00 am	RNS	Corporate Update
22nd Sep 2021	4:36 pm	RNS	Price Monitoring Extension
24th Aug 2021	11:07 am	RNS	Director/PDMR Shareholding
20th Aug 2021	4:40 pm	RNS	Second Price Monitoring Extn
20th Aug 2021	4:35 pm	RNS	Price Monitoring Extension
19th Aug 2021	4:35 pm	RNS	Price Monitoring Extension
17th Aug 2021	8:50 am	RNS	Notification of Major Holdings
12th Aug 2021	7:00 am	RNS	FDA approves the Lupzuor™ PK study

Latest Share Chat

Immupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

Intraday Immupharma Share Chart

Share Price Volatility

Please enter at least 2 characters

No results found

Search results

Recently viewed

Trending